Bigfoot Biomedical

Insulet product offering
Insulet acquires Bigfoot's insulin pump patents for $25M
By Jessica Hagen | 03:20 pm | February 13, 2023
The Omnipod maker purchased assets related to Bigfoot Biomedical's pump-based automated insulin delivery technology.
Hand holding Bigfoot rapid-acting smart insulin pen
FDA greenlights Bigfoot Biomedical's insulin recommending diabetes management system
By Mallory Hackett | 12:58 pm | May 10, 2021
The system was cleared for use among individuals 12 years old and up with Type 1 or Type 2 diabetes on multiple-dose injection therapy.  
Bigfoot Biomedical caps off its Series C funding at $55M, including a new $10M addition
By Laura Lovett | 02:55 pm | June 03, 2020
Pharma giant Abbott led the round with participation from Quadrant Capital Advisors Senvest Capital, Janus Henderson, Cormorant Asset Management and other funders. 
Bigfoot Biomedical announces $45M Series C tranche, expands partnership with Abbott
By Dave Muoio | 12:31 pm | January 16, 2020
Bigfoot has agreed to develop and commercialize new programs that will integrate with Abbott's diabetes management platform.
Bigfoot Biomedical closes Series B financing round with $55M
By Laura Lovett | 04:38 pm | March 28, 2018
A diabetes startup that uses artificial intelligence, Bigfoot Biomedical, has just announced that it scored a total of $55 million in Series B equity financing with new investments from Abbott and other existing funders.